Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Acquired by Wellington Management Group LLP

Posted by Stanley Muller on Aug 30th, 2026

Wellington Management Group LLP lifted its stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Free Report) by 1.6% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,379,433 shares of the company’s stock after purchasing an additional 119,146 shares during the period. Wellington Management Group LLP owned about 0.11% of Structure Therapeutics worth $396,054,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Avoro Capital Advisors LLC lifted its stake in Structure Therapeutics by 21.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company’s stock valued at $455,939,000 after buying an additional 1,150,000 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of Structure Therapeutics by 5.2% during the first quarter. Janus Henderson Group PLC now owns 5,354,981 shares of the company’s stock valued at $258,260,000 after acquiring an additional 264,833 shares during the last quarter. BVF Inc. IL lifted its position in shares of Structure Therapeutics by 8.6% in the fourth quarter. BVF Inc. IL now owns 3,479,022 shares of the company’s stock valued at $241,966,000 after acquiring an additional 275,105 shares in the last quarter. Morgan Stanley boosted its stake in shares of Structure Therapeutics by 261.4% in the fourth quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock worth $145,209,000 after acquiring an additional 1,510,093 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of Structure Therapeutics by 36.6% in the first quarter. Principal Financial Group Inc. now owns 1,753,764 shares of the company’s stock worth $84,531,000 after acquiring an additional 469,554 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on GPCR. Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Friday, July 17th. Citigroup reissued a “market outperform” rating on shares of Structure Therapeutics in a research note on Friday, August 7th. Citizens Jmp lowered their price target on shares of Structure Therapeutics from $113.00 to $110.00 and set a “market outperform” rating on the stock in a research report on Friday, August 7th. Wall Street Zen raised shares of Structure Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday, August 17th. Finally, HC Wainwright decreased their target price on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a research note on Thursday, June 11th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $110.91.

Read Our Latest Research Report on GPCR

Structure Therapeutics Stock Down 3.8%

Shares of GPCR opened at $47.37 on Friday. Structure Therapeutics Inc. Sponsored ADR has a 52-week low of $18.26 and a 52-week high of $94.90. The stock has a fifty day simple moving average of $50.80 and a two-hundred day simple moving average of $50.50. The company has a market capitalization of $3.30 billion, a PE ratio of -47.37 and a beta of -1.43.

Structure Therapeutics (NASDAQ:GPCR – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, equities analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -1.84 earnings per share for the current fiscal year.

Structure Therapeutics Profile

(Free Report)

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.